Eli Lilly and Co — AI technical analysis, September 2026
NYSE/NASDAQ · Pharmaceuticals
AI Recommendation
BUY
Technical score 90/100
Last price: $1136.11 · 52W range $712.05 – $1292.65
Short answer
Should you buy LLY right now? Stockgaide's AI rates LLY as
BUY, with a technical score of
90/100 at a last price of $1136.11.
The 50-day average is above the 200-day average, and RSI sits at 16.3.
Wall Street's consensus rating is 1.95/5.
Full AI analysis for LLY
Strategic Conclusion
Recommendation: Buy
Why? LLY remains in a medium-term uptrend with SMA50 above SMA200, and the RSI at 16.3 is deeply oversold — historically a rebound zone. The analyst consensus is firmly Buy (1.95), and the high P/E is supported by strong growth expectations. Short-term momentum is negative (MACD below signal), but the risk/reward at current levels favors accumulation rather than avoidance.
Ideal profile: Long-term investor comfortable with volatility; not ideal for short-term traders until MACD turns positive.
Price range: Entry zone $1,100–$1,140; target $1,250–$1,290; stop-loss below $1,050.
Practical action: Buy in tranches at current levels and add on dips toward $1,100. Avoid chasing above $1,180 until momentum confirms a reversal.
1. Recent Price & Momentum
Current price $1,138.28 is 12% below the 52-week high of $1,292.65 and 60% above the 52-week low of $712.05 — sitting in the upper-middle part of the range.
Price is below SMA50 ($1,183.14) but above SMA200 ($1,065.19), indicating a pullback within a longer-term uptrend.
Short-term scenario: oversold bounce likely, but a break below $1,065 would signal a deeper correction; a reclaim of $1,183 would restore bullish momentum.
2. Valuation (P/E)
P/E TTM of 39.9 is high versus the broader market and most pharma peers, reflecting priced-in growth from GLP-1 drugs.
The multiple is not cheap, but for a company with LLY’s earnings trajectory, it is within acceptable territory. Further upside depends on continued execution and pipeline progress.
RSI(14) at 16.3: extremely oversold, historically a strong rebound signal.
MACD: -18.28 vs signal -10.69, histogram negative — bearish momentum still in control.
Technical score: 90/100 → BUY, driven by trend structure, oversold RSI, and analyst support, despite short-term MACD weakness.
4. Analyst Consensus
Mean rating 1.95/5 with 30 buy, 7 hold, 1 sell — clearly bullish.
This aligns with the long-term technical trend and oversold condition, but diverges from the immediate MACD momentum. The consensus supports buying the dip rather than waiting for lower prices.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 90/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is below its signal line — bearish momentum.
RSI at 16.28 — oversold, potential rebound zone.
Wall Street consensus rating of 1.95 — analysts lean Buy.
Stockgaide's AI currently rates LLY as BUY, with a technical score of 90 out of 100 at a last price of $1136.11. This is educational content, not investment advice.
Is LLY in an uptrend?
LLY's 50-day moving average (1183.14) is above its 200-day moving average (1065.19), which points to a medium-term uptrend.
What is LLY's RSI today?
LLY has a 14-day RSI of 16.3, which places it in oversold territory (above 70 is overbought, below 30 is oversold).
What do analysts say about LLY?
Wall Street analysts covering LLY have a consensus rating of 1.95 out of 5 (1 = Strong Buy), meaning they lean Buy — 30 Buy · 7 Hold · 1 Sell.
Where is LLY trading in its 52-week range?
LLY last traded at $1136.11, against a 52-week range of $712.05 to $1292.65 — about 73% of the way up that range.
Get the full AI analysis of LLY
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.